Phase 3 trial for BNT311/GEN1046 (acasunlimab) in second line NSCLC
Latest Information Update: 08 Aug 2024
At a glance
- Drugs Acasunlimab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 05 Aug 2024 According to a BioNTech media release, the emerging clinical profile of BNT311/GEN1046 (acasunlimab) is encouraging, for reasons relating to portfolio strategy, BioNTech opted not to participate in the further development of the program, including a planned Phase 3 trial. BioNTech and Genmab A/S will continue their collaboration under the existing agreements which was expanded in 2022.
- 05 Aug 2024 According to a Genmab media release, company plans to initiate the Phase 3 study in the second half of this year.
- 20 Mar 2024 According to OmniAB media release,the company plans to initiate a Phase 3 study of acasunlimab in a second-line NSCLC indication in before year-end 2024.